Form 4: Acadia Pharmaceuticals Executive Acquires Stock Options and Restricted Stock Units

Elizabeth H.Z. Thompson, EVP, Head of Research & Development at Acadia Pharmaceuticals, reports acquisition of stock options and restricted stock units.

Summary

• On August 12, 2024, Elizabeth H.Z. Thompson, EVP, Head of Research & Development at Acadia Pharmaceuticals, acquired stock options for 324,582 shares and 64,544 restricted stock units.
• The stock options have an exercise price of $15.29 and expire on August 11, 2034.
• 25% of the stock options will vest on July 29, 2025, with the remainder vesting in 36 equal monthly installments thereafter.
• 50% of the restricted stock units vest on July 29, 2026, 25% on July 29, 2027, and 25% on July 29, 2028.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard executive compensation disclosure. The acquisition of stock options and restricted stock units could be seen as a positive sign, but it's not a major event.

Positives

• The acquisition of stock options and restricted stock units by a key executive could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Executive compensation in the pharmaceutical industry often includes stock options and restricted stock units to align management's interests with those of shareholders and incentivize long-term value creation.

Comparison to Industry Standards

• Stock option grants are a common component of executive compensation packages in the pharmaceutical industry.
• Companies like Biogen, Amgen, and Gilead Sciences also utilize stock options and restricted stock units to incentivize their executives.
• The vesting schedules and exercise prices are generally aligned with industry norms to promote long-term performance and retention.

Stakeholder Impact

• The vesting of stock options and restricted stock units could potentially dilute existing shareholders' equity over time.

Key Dates